BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/11/2014 2:06:00 PM | Browse: 622 | Download: 480
Publication Name World Journal of Clinical Oncology
Manuscript ID 8313
Country/Territory Mexico
2013-12-25 09:32
Peer-Review Started
2013-12-25 16:43
To Make the First Decision
2014-03-12 17:05
Return for Revision
2014-03-21 20:41
2014-04-08 08:31
Second Decision
2014-05-29 08:48
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-05-29 09:33
Articles in Press
2014-05-29 10:57
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-07-24 14:17
Publish the Manuscript Online
2014-12-11 14:23
ISSN 2218-4333 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Review
Article Title Immune therapy for human papillomaviruses-related cancers
Manuscript Source Invited Manuscript
All Author List Ricardo Rosales and Carlos Rosales
Funding Agency and Grant Number
Funding Agency Grant Number
Virolab, S de RL de CV
Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México IN207514(In part)
Consejo Nacional de Ciencia y Tecnología, Mexico 168098
Corresponding Author Dr. Carlos Rosales Departamento de Inmunología, Instituto de Investigaciones Biomédicas - UNAM, Apdo. Postal 70228, Cd. Universitaria, México D.F. - 04510, MEXICO
Key Words Human papillomavirus; T cell; Immunoglobulin; Antibody; Vaccinia virus
Core Tip Infection with human papillomavirus (HPV) is very common and it is associated with benign and malignant proliferation of skin and mucosae. Low-risk HPV produce warts; while high-risk HPV induce tumors. Because there are not antiviral drugs for HPV infection, current therapies involve surgical removal of the lesion. Unfortunately, after surgery many recurrences still appear and about 50% of the HPV-cancer patients die. In the past decade, new therapeutic strategies geared to generate an efficient virus-specific cytotoxic response have been developed. This review describes the current status of the several therapeutic strategies used to treat HPV-induced lesions.
Publish Date 2014-12-11 14:23
Citation Rosales R, Rosales C. Immune therapy for human papillomaviruses-related cancers. World J Clin Oncol 2014; 5(5): 1002-1019
Url http://www.wjgnet.com/2218-4333/full/v5/i5/1002.htm
DOI http://dx.doi.org/10.5306/wjco.v5.i5.1002
Full Article (PDF) WJCO-5-1002.pdf
Full Article (Word) WJCO-5-1002.doc
Manuscript File 8313-Review.docx
Answering Reviewers 8313-Answering reviewers.pdf
Copyright License Agreement 8313-Copyright assignment.pdf
Peer-review Report 8313-Peer review(s).pdf
Scientific Misconduct Check 8313-CrossCheck.jpg
Scientific Editor Work List 8313-Scientific editor work list.pdf